The Chinese medicinal known as Antivirus(ATVC) Compound was studied for HBV-fighting action by vitro experiment and clinical research. Method:HBV-DNA transfected cell line(2.2.15 cell strain) were used in vitro experiment. Clinically chronic HBV group(60 cases) and control group(57 cases) were observed for negative conversion rates after three, six month of treatment. Result:therapeutic indexes of ATVC on HBsAg and HBeAg were respectively31.75 and 36.27; and ATVC inhibited HBV-DNA in a dose-dependent manner. Negative conversion rates of HBeAg and HBV-DNA in chronic HBV group were 47.8% and 54.9%, higher than those of the control group (P<0.05). There were little difference between three and six months of treatment. Conclusion:as the research suggested, ATVC apparently inhibit HBV both in vitro and in vivo, and proved satisfying therapeutic effects.